Biora Therapeutics (BIOR) Competitors $0.16 -0.03 (-14.21%) As of 01/17/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends BIOR vs. QLGN, DWTX, INM, MYMD, SCNI, ARAV, TTNP, MTNB, TCRT, and VCNXShould you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Qualigen Therapeutics (QLGN), Dogwood Therapeutics (DWTX), InMed Pharmaceuticals (INM), MyMD Pharmaceuticals (MYMD), Scinai Immunotherapeutics (SCNI), Aravive (ARAV), Titan Pharmaceuticals (TTNP), Matinas Biopharma (MTNB), Alaunos Therapeutics (TCRT), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry. Biora Therapeutics vs. Qualigen Therapeutics Dogwood Therapeutics InMed Pharmaceuticals MyMD Pharmaceuticals Scinai Immunotherapeutics Aravive Titan Pharmaceuticals Matinas Biopharma Alaunos Therapeutics Vaccinex Biora Therapeutics (NASDAQ:BIOR) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership. Do institutionals and insiders believe in BIOR or QLGN? 43.7% of Biora Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 51.1% of Biora Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, BIOR or QLGN? Qualigen Therapeutics has higher revenue and earnings than Biora Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiora Therapeutics$892K0.83-$124.11M-$13.04-0.01Qualigen Therapeutics$4.98M0.60-$13.42MN/AN/A Does the media prefer BIOR or QLGN? In the previous week, Biora Therapeutics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score. Company Overall Sentiment Biora Therapeutics Neutral Qualigen Therapeutics Neutral Does the MarketBeat Community prefer BIOR or QLGN? Biora Therapeutics received 1 more outperform votes than Qualigen Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Qualigen Therapeutics an outperform vote while only 80.00% of users gave Biora Therapeutics an outperform vote. CompanyUnderperformOutperformBiora TherapeuticsOutperform Votes880.00% Underperform Votes220.00% Qualigen TherapeuticsOutperform Votes787.50% Underperform Votes112.50% Which has more risk and volatility, BIOR or QLGN? Biora Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of -0.69, suggesting that its stock price is 169% less volatile than the S&P 500. Do analysts rate BIOR or QLGN? Biora Therapeutics presently has a consensus target price of $23.00, indicating a potential upside of 14,010.43%. Given Biora Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Biora Therapeutics is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biora Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BIOR or QLGN more profitable? Company Net Margins Return on Equity Return on Assets Biora TherapeuticsN/A N/A -332.47% Qualigen Therapeutics N/A N/A -424.18% SummaryBiora Therapeutics beats Qualigen Therapeutics on 9 of the 12 factors compared between the two stocks. Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOR vs. The Competition Export to ExcelMetricBiora TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$737,000.00$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-0.019.8789.3417.36Price / Sales0.83309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book0.006.055.314.79Net Income-$124.11M$154.90M$122.54M$225.00M7 Day Performance-4.73%-0.32%0.59%2.62%1 Month Performance-71.15%0.43%2.55%3.81%1 Year Performance-98.21%3.08%25.29%20.10% Biora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIORBiora Therapeutics2.3194 of 5 stars$0.16-14.2%$23.00+14,010.4%-98.2%$737,000.00$892,000.00-0.01120Gap DownQLGNQualigen TherapeuticsN/A$4.20-1.9%N/A-83.8%$3.09M$4.98M0.0050Positive NewsDWTXDogwood TherapeuticsN/A$2.32-1.7%N/AN/A$3.09MN/A-0.355Gap UpINMInMed Pharmaceuticals1.0113 of 5 stars$4.21-2.3%N/A-31.0%$3.05M$4.96M-0.3010Positive NewsMYMDMyMD PharmaceuticalsN/A$1.27-1.2%N/A-79.1%$3.00MN/A0.009SCNIScinai Immunotherapeutics0.8961 of 5 stars$3.46-2.0%N/A-36.2%$2.95M$452,000.00-0.0120Positive NewsGap UpARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M-0.0420TTNPTitan Pharmaceuticals0.5295 of 5 stars$3.21-3.9%N/A-37.6%$2.93M$180,000.000.0010Analyst ForecastNews CoverageMTNBMatinas BiopharmaN/A$0.57-8.5%N/AN/A$2.88M$1.10M-0.1230TCRTAlaunos Therapeutics0.1254 of 5 stars$1.74+2.4%N/A-90.0%$2.79M$7,000.000.0040Positive NewsVCNXVaccinexN/A$1.05-8.7%N/A-86.0%$2.73M$388,000.00-0.0240Gap Down Related Companies and Tools Related Companies Qualigen Therapeutics Competitors Dogwood Therapeutics Competitors InMed Pharmaceuticals Competitors MyMD Pharmaceuticals Competitors Scinai Immunotherapeutics Competitors Aravive Competitors Titan Pharmaceuticals Competitors Matinas Biopharma Competitors Alaunos Therapeutics Competitors Vaccinex Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIOR) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
